Toggle navigation
Menu
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
73°
Search
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Local Weather
News
Sports
Entertainment
Calendar
Games
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Town & Gown
Subscribe
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
Gold
Crude Oil
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries
Gilead Sciences
(NQ:
GILD
)
66.94
USD
-0.04 (-0.06%)
Official Closing Price
Updated: 7:59 PM EST, Jan 22, 2021
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press releases about Gilead Sciences
< Previous
1
2
3
4
5
6
7
8
9
...
77
78
Next >
Gilead Sciences to Release Fourth Quarter and Full Year 2020 Financial Results on Thursday, February 4, 2021
January 21, 2021
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2020 financial results will be released on Thursday, February 4, after the market closes. At 4:30 p.m. Eastern...
From
Business Wire News Releases
Francesco M. Marincola Joins Kite as Worldwide Head of Cell Therapy Research
January 19, 2021
Kite, a Gilead Company (Nasdaq: GILD), today announced that Francesco Marincola, MD, will join the company as Senior Vice President and Global Head of Cell Therapy Research, effective February 1. Dr....
From
Business Wire News Releases
Gilead and Vir Biotechnology Establish Clinical Collaboration to Explore Combination Strategies for Functional Cure for Chronic Hepatitis B Virus
January 12, 2021
Gilead Sciences, Inc. (NASDAQ: GILD) and Vir Biotechnology, Inc. (NASDAQ: VIR) today announced that the companies have entered into a clinical collaboration to evaluate novel therapeutic combination...
From
Business Wire News Releases
Gilead and Vir Biotechnology Establish Clinical Collaboration to Explore Combination Strategies for Functional Cure for Chronic Hepatitis B Virus
January 12, 2021
From
GlobeNewswire News Releases
Thinking about trading options or stock in Eli Lilly, Gilead Sciences, GameStop, Boeing, or Roku?
January 11, 2021
InvestorsObserver issues critical PriceWatch Alerts for LLY, GILD, GME, BA, and ROKU.
From
PR Newswire
Gilead Sciences Announces Updated 2020 Guidance
January 11, 2021
Gilead Sciences, Inc. (Nasdaq: GILD) today announced the company has revised certain elements of its full year 2020 guidance.
From
Business Wire News Releases
Kite and Oxford BioTherapeutics Establish Cell Therapy Research Collaboration in Blood Cancers and Solid Tumors
January 06, 2021
Kite, a Gilead Company (Nasdaq: GILD), and Oxford BioTherapeutics Ltd. (OBT), a clinical stage oncology company with a pipeline of immuno-oncology (IO) and antibody-drug conjugate (ADC)-based...
From
Business Wire News Releases
Gilead Sciences to Present at the 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021
December 21, 2020
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Daniel O’Day, Gilead’s Chairman and Chief Executive Officer, will provide an overview of the company at the 39th Annual J.P. Morgan Healthcare...
From
Business Wire News Releases
Glioblastoma Multiforme (GBM) Treatments Advancing as FDA Steps Up Measures Due to Rising Incidences
December 17, 2020
Tags
Featured News
From
FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Glioblastoma Multiforme (GBM) Treatments Advancing as FDA Steps Up Measures Due to Rising Incidences
December 17, 2020
Financialnewsmedia.com News Commentary
From
PR Newswire
Kite’s Tecartus™ (KTE-X19) Granted Conditional Marketing Authorization for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma in Europe
December 16, 2020
Kite, a Gilead Company (Nasdaq: GILD), today announced that the European Commission has granted conditional marketing authorization for Tecartus™ (autologous, anti-CD19-transduced CD3+ cells; formerly...
From
Business Wire News Releases
Gilead and Galapagos Announce New Commercialization and Development Agreement for Jyseleca® (Filgotinib)
December 15, 2020
Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & Nasdaq: GLPG) today announced that the companies have agreed to amend their existing arrangement for the commercialization and...
From
Business Wire News Releases
Gilead and Galapagos announce New Commercialization and Development Agreement for Jyseleca® (filgotinib)
December 15, 2020
From
GlobeNewswire News Releases
Gilead Advances Oncology Portfolio With New Data From Phase 3 ASCENT Trial of Trodelvy® in Metastatic Triple Negative Breast Cancer
December 10, 2020
Gilead Sciences, Inc. (Nasdaq: GILD) is presenting new data from the Phase 3 ASCENT trial of Trodelvy® (sacituzumab govitecan-hziy) in metastatic triple-negative breast cancer (mTNBC) at the 2020 San...
From
Business Wire News Releases
Gilead Sciences to Acquire MYR GmbH
December 10, 2020
- Gilead to Acquire Hepcludex™, a First-in-Class Entry Inhibitor, for Treatment of Chronic Hepatitis Delta Virus (HDV), Adding Immediate Revenue After Closing of Transaction -
From
PR Newswire
Gilead Sciences to Acquire MYR GmbH
December 10, 2020
Gilead Sciences, Inc. (Nasdaq: GILD) and MYR GmbH, a German biotechnology company focused on the development and commercialization of therapeutics for the treatment of chronic hepatitis delta virus...
From
Business Wire News Releases
Gilead Announces Racial Equity Community Impact Fund to Support Black Communities Across United States
December 09, 2020
Gilead Sciences, Inc. (Nasdaq: GILD) today announced the launch of its Racial Equity Community Impact Fund, which will support high-impact organizations working to tackle racial inequities affecting...
From
Business Wire News Releases
Jeffrey A. Bluestone Joins Gilead Sciences’ Board of Directors
December 08, 2020
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Jeffrey A. Bluestone, PhD, has been appointed to the company’s Board of Directors.
From
Business Wire News Releases
Matinas BioPharma Announces Collaboration with the National Institute of Allergy and Infectious Diseases to Evaluate Oral Formulations of Gilead’s Antiviral Remdesivir Utilizing Matinas’ LNC Platform
December 07, 2020
From
GlobeNewswire News Releases
Yescarta® Shows Positive Results as a First-Line Treatment for Patients With High-Risk Large B-cell Lymphoma
December 06, 2020
Kite, a Gilead Company (Nasdaq: GILD), today announced results from the interim analysis of ZUMA-12, a multicenter, open-label, single-arm Phase 2 study evaluating Yescarta® (axicabtagene ciloleucel)...
From
Business Wire News Releases
Magrolimab Demonstrates Clinical Responses in Ongoing Phase 1b Trial of Previously Untreated Acute Myeloid Leukemia Patients
December 06, 2020
Gilead Sciences, Inc. (Nasdaq: GILD) today announced updated results from the magrolimab Phase 1b trial. Magrolimab is an investigational, potential first-in-class, anti-CD47 monoclonal antibody being...
From
Business Wire News Releases
Yescarta® Is First CAR T-cell Therapy to Demonstrate High Response Rates and Durable Clinical Benefit in a Pivotal Indolent Non-Hodgkin Lymphoma Study
December 05, 2020
Kite, a Gilead Company (Nasdaq: GILD), today announced results from the primary analysis of ZUMA-5, a global, multicenter, single-arm, open-label Phase 2 study evaluating Yescarta® (axicabtagene...
From
Business Wire News Releases
New Four-Year Data Show Long-Term Survival in Patients With Large B-Cell Lymphoma Treated With Yescarta® in ZUMA-1 Trial
December 05, 2020
Kite, a Gilead Company (Nasdaq: GILD), today announced four-year follow-up data from the pivotal ZUMA-1 trial of Yescarta® (axicabtagene ciloleucel) in adult patients with refractory large B-cell...
From
Business Wire News Releases
New Data for TecartusTM Demonstrate Durable Responses at One Year Follow-Up in Relapsed or Refractory Mantle Cell Lymphoma
December 05, 2020
Kite, a Gilead Company (Nasdaq: GILD), today announced follow-up results from the pivotal ZUMA-2 trial of Tecartus™ (brexucabtagene autoleucel, formerly KTE-X19) in adult patients with relapsed or...
From
Business Wire News Releases
InvestorNewsBreaks – A Glimpse into Robinhood’s 100 Most Popular Stocks
December 03, 2020
From
InvestorBrandNetwork
BioMedNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Featured in Korea Biomedical Review Article
November 24, 2020
From
InvestorBrandNetwork
Gilead Sciences to Present at the 3rd Annual Evercore ISI HealthCONx Conference on Wednesday, December 2, 2020
November 23, 2020
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Johanna Mercier, Chief Commercial Officer, and Merdad Parsey, MD, PhD, Chief Medical Officer, will participate in a fireside chat at the 3rd...
From
Business Wire News Releases
Gilead Announces Investigational Long-Acting HIV-1 Capsid Inhibitor, Lenacapavir, Achieves Primary Endpoint in Phase 2/3 Study in Heavily Treatment-Experienced People Living With HIV
November 18, 2020
Gilead Sciences, Inc. (Nasdaq: GILD) today announced topline results from the Phase 2/3 CAPELLA trial evaluating the company’s investigational, long-acting HIV-1 capsid inhibitor, lenacapavir, in...
From
Business Wire News Releases
Gilead and Novo Nordisk Present New Data from Proof-of-Concept Trial in NASH
November 15, 2020
Gilead Sciences, Inc. (Nasdaq: GILD) and Novo Nordisk A/S (NASDAQ Copenhagen: NOVO B) today announced results from a Phase 2 proof-of-concept trial. The five-arm trial evaluated combinations of Novo...
From
Business Wire News Releases
Gilead and Kite to Share Latest Scientific Advances in Hematologic Malignancies at ASH 2020
November 05, 2020
Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, today announced that 16 abstracts, including three oral presentations from the companies’ combined immuno-oncology research and...
From
Business Wire News Releases
< Previous
1
2
3
4
5
6
7
8
9
...
77
78
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.